Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.

@article{Napolitano2014OptimalDO,
  title={Optimal duration of low molecular weight heparin for the treatment of cancer-related deep vein thrombosis: the Cancer-DACUS Study.},
  author={M. Napolitano and Giorgia Saccullo and A. Malato and D. Sprini and W. Ageno and Davide Imberti and D. Mascheroni and E. Bucherini and Pina Gallucci and A. D’Alessio and T. Prantera and P. Spadaro and S. Rotondo and P. di Micco and V. Oriana and Oreste Urbano and F. Recchia and A. Ghirarduzzi and L. Lo Coco and S. Mancuso and A. Casuccio and G. B. Rini and S. Siragusa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2014},
  volume={32 32},
  pages={
          3607-12
        }
}
  • M. Napolitano, Giorgia Saccullo, +20 authors S. Siragusa
  • Published 2014
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • PURPOSE We evaluated the role of residual vein thrombosis (RVT) to assess the optimal duration of anticoagulants in patients with cancer who have deep vein thrombosis (DVT) of the lower limbs. PATIENTS AND METHODS Patients with active cancer and a first episode of DVT treated with low molecular weight heparin (LMWH) for 6 months were eligible. Patients were managed according to RVT findings: those with RVT were randomly assigned to continue LMWH for an additional 6 months (group A1) or to… CONTINUE READING
    View on PubMed
    iris.unipa.it
    62 Citations
    Highly Influential Citations
    2
    Background Citations
    11
    Methods Citations
    2

    Supplemental Clinical Trials

    Interventional Clinical Trial
    Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
    The duration of anticoagulant treatment in cancer patients with Deep Vein Thrombosis (DVT) of the lower limbs is still uncertain. The present study addresses the possible role of the… Expand
    ConditionsCancer, Deep Vein Thrombosis
    InterventionDrug
    Azienda Ospedaliera Universitaria Policlinico
    March 2005 - March 2011
    Explore Further
    Discover more papers related to the topics discussed in this paper
    62 Citations
    Citation Type

    Citation Type

    Should anticoagulation therapy be withheld in patients with active cancer after 6 months of low-molecular weight heparin?
    • 1
    Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
    • A. Young, A. Marshall, +15 authors M. Levine
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2018
    • 442
    • PDF
    Baseline Analysis on the Outcome of Patients with Deep Vein Thrombosis (DVT) Before the Global Impact of New Oral Anticoagulants in Italy: Data from RIETE Registry
    • 11
    • PDF
    Quality of Life in Patients With Cancer Under Prolonged Anticoagulation for High-Risk Deep Vein Thrombosis: a Long-Term Follow-Up
    • 1
    Residual vein obstruction in patients diagnosed with acute isolated distal deep vein thrombosis associated with active cancer
    • 3
    D-dimer and high-sensitivity C-reactive protein levels to predict venous thromboembolism recurrence after discontinuation of anticoagulation for cancer-associated thrombosis
    • 14
    • PDF
    Tinzaparin in cancer associated thrombosis beyond 6months: TiCAT study.
    • 47
    The Current Status of Direct Oral Anticoagulants in Cancer-Related Venous Thromboembolism Treatment
    The Efficacy and Safety of Low Molecular Weight Heparin Administration to Improve Survival of Cancer Patients: A Systematic Review and Meta-Analysis.
    • 2
    Residual Clot in Patients with Deep Vein Thrombosis and Pulmonary Embolism: Prognostic Implications Keywords: Deep vein thrombosis; Pulmonary embolism;
    • PDF

    References

    SHOWING 1-10 OF 29 REFERENCES
    Residual vein thrombosis for assessing duration of anticoagulation after unprovoked deep vein thrombosis of the lower limbs: The extended DACUS study
    • 41
    • PDF
    Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: the Duration of Anticoagulation based on Compression UltraSonography (DACUS) study.
    • 120
    • PDF
    Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    • 1,866
    • PDF
    Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer.
    • 520
    • Highly Influential
    The effect of low molecular weight heparin on survival in patients with advanced malignancy.
    • 555
    Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study.
    • 374
    • PDF
    Residual Venous Thrombosis as a Predictive Factor of Recurrent Venous Thromboembolism
    • 487
    Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).
    • 618
    Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. Warfarin Optimal Duration Italian Trial Investigators.
    • 514
    • PDF
    D-dimer testing to determine the duration of anticoagulation therapy.
    • 432